The Proteolytic Regulation of Virus Cell Entry by Furin and Other Proprotein Convertases

Viruses

Volumn 11, Issue 9, 2019, Pages

  Izaguirre, Gonzalo ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

furin; proprotein convertases; protease inhibitors; proteases

Indexed keywords

FURIN; SERINE PROTEINASE;

ANIMAL; CHEMISTRY; ENZYMOLOGY; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; VIRAL PHENOMENA AND FUNCTIONS; VIROLOGY; VIRUS; VIRUS ENTRY; VIRUS INFECTION;

ANIMALS; FURIN; HOST-PATHOGEN INTERACTIONS; HUMANS; PROPROTEIN CONVERTASES; VIRUS DISEASES; VIRUS INTERNALIZATION; VIRUS PHYSIOLOGICAL PHENOMENA; VIRUSES;

EID: 85072014347     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/V11090837     Document Type: Review

References (145)

1. Seidah, N.G.; Mayer, G.; Zaid, A.; Rousselet, E.; Nassoury, N.; Poirier, S.; Essalmani, R.; Pra, A. The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 2008, 40, 1111–1125. [CrossRef] [PubMed]
2. Seidah, N.G.; Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 2010, 11, 367–383. [CrossRef]
3. Basak, A.; Zhong, M.; Munzer, J.S.; Michel Chretien, M.; Seidah, N.G. Implication of the proprotein convertases furin, PC5 and PC7 in the cleavage of surface glycoproteins of Hong Kong, Ebola and respiratory syncytial viruses: A comparative analysis with fluorogenic peptides. Biochem. J. 2001, 353, 537–545. [CrossRef] [PubMed]
4. Artenstein, A.W.; Opal, S.M. Proprotein convertases in health and disease. N. Engl. J. Med. 2011, 365, 2507–2518. [CrossRef] [PubMed]
5. Couture, F.; D’Anjou, F.; Day, R. On the cutting edge of proprotein convertase pharmacology: From molecular concepts to clinical applications. Biomol. Concepts 2011, 2, 421–438. [CrossRef] [PubMed]
6. Omotuyi, I.O. Ebola virus envelope grycoprotein derived peptide in human furin-bound state: Computational studies. J. Biomol. Struct. Dyn. 2015, 33, 461–470. [CrossRef] [PubMed]
7. Dahms, S.O.; Arciniega, M.; Steinmetzer, T.; Huber, R.; Than, M.E. Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism. Proc. Natl. Acad. Sci. USA 2016, 113, 11196–11201. [CrossRef]
8. Izaguirre, G.; Qi, L.; Lima, M.; Olson, S.T. Identification of serpin determinants of specificity and selectivity for furin inhibition through studies of α1-PDX (α1-proteinase inhibitor Portland)-serpin B8 and furin active-site loop chimeras. J. Biol. Chem. 2013, 288, 21802–21814. [CrossRef]
9. Izaguirre, G.; Arciniega, M.; Quezada, A.G. Specific and selective inhibitors of proprotein convertases engineered by transferring serpin B8 reactive-site and exosite determinants of reactivity to the serpin α1PDX. Biochemistry 2019, 58, 1679–1688. [CrossRef]
10. Garten, W.; Hallenberger, S.; Ortmann, D.; Schäfer, W.; Vey, M.; Angliker, H.; Shaw, E.; Klenk, H.D. Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones. Biochimie 1994, 76, 217–225. [CrossRef]
11. Remacle, A.G.; Shiryaev, S.A.; Oh, E.S.; Cieplak, P.; Srinivasan, A.; Wei, G.; Liddington, R.C.; Ratnikov, B.I.; Parent, A.; Desjardins, R.; et al. Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J. Biol. Chem. 2008, 283, 20897–20906. [CrossRef] [PubMed]
12. Shiryaev, S.A.; Chernov, A.V.; Golubkov, V.S.; Thomsen, E.R.; Chudin, E.; Chee, M.S.; Kozlov, I.A.; Strongin, A.Y.; Cieplak, P. High-resolution analysis and functional mapping of cleavage sites and substrate proteins of furin in the human proteome. PLoS ONE 2013, 8, e54290. [CrossRef] [PubMed]
13. Tian, S. A 20 Residues motif delineates the furin cleavage site and its physical properties may influence viral fusion. Biochem. Insights 2009, 2, 9–20. [CrossRef]
14. Silverman, G.A.; Bird, P.I.; Carrell, R.W.; Church, F.C.; Coughlin, P.B.; Gettins, P.G.; Irving, J.A.; Lomas, D.A.; Luke, C.J.; Moyer, R.W.; et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 2001, 276, 33293–33296. [CrossRef] [PubMed]
15. Dahlen, J.R.; Jean, F.; Thomas, G.; Foster, D.C.; Kisiel, W. Inhibition of soluble recombinant furin by human proteinase inhibitor 8. J. Biol. Chem. 1998, 273, 1851–1854. [CrossRef] [PubMed]
16. Leblond, J.; Laprise, M.H.; Gaudreau, S.; Grondin, F.; Kisiel, W.; Dubois, C.M. The serpin proteinase inhibitor 8. An endogenous furin inhibitor released from human platelets. Thromb. Haemost. 2006, 95, 243–252. [CrossRef] [PubMed]
17. Osterwalder, T.; Kuhnen, A.; Leiserson, W.M.; Kim, Y.S.; Keshishian, H. Drosophila serpin 4 functions as a neuroserpin-like inhibitor of subtilisin-like proprotein convertases. J. Neurosci. 2004, 24, 5482–5491. [CrossRef] [PubMed]
18. Richer, M.J.; Keays, C.A.; Waterhouse, J.; Minhas, J.; Hashimoto, C.; Jean, F. The Spn4 gene of Drosophila encodes a potent furin-directed secretory pathway serpin. Proc. Natl. Acad. Sci. USA 2004, 101, 10560–10565. [CrossRef]
19. Bentele, C.; Krüger, O.; Tödtmann, U.; Oley, M.; Ragg, H. A proprotein convertase-inhibiting serpin with an endoplasmic reticulum targeting signal from Branchiostoma lanceolatum, a close relative of vertebrates. Biochem. J. 2006, 395, 449–456. [CrossRef]
20. Fugere, M.; Day, R. Cutting back on pro-protein convertases: The latest approaches to pharmacological inhibition. Trends Pharmacol. Sci. 2005, 26, 294–301. [CrossRef]
21. Anderson, E.D.; Thomas, L.; Hayflick, J.S.; Thomas, G. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed a1-antitrypsin variant. J. Biol. Chem. 1993, 268, 24887–24891. [PubMed]
22. Schiller, J.T.; Day, P.M.; Kines, R.C. Current understanding of the mechanism of HPV infection. Gyn. Oncol. 2010, 118, S12–S17. [CrossRef] [PubMed]
23. Day, P.M.; Schiller, J.T. The role of furin in papillomavirus infection. Future Microbiol. 2009, 4, 1255–1262. [CrossRef] [PubMed]
24. Kines, R.C.; Thompson, C.D.; Lowy, D.R.; Schiller, J.T.; Day, P.M. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. USA 2009, 106, 2458–20463. [CrossRef] [PubMed]
25. Richards, R.M.; Lowy, D.R.; Schiller, J.T.; Day, P.M. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. USA 2006, 103, 1522–1527. [CrossRef]
26. Bronnimann, M.P.; Calton, C.M.; Chiquette, S.F.; Li, S.; Lu, M.; Janice, A.; Chapman, J.A.; Bratton, K.N.; Schlegel, A.M.; Campos, S.K. Furin cleavage of L2 during papillomavirus infection: Minimal dependence on cyclophilins. J. Virol. 2016, 90, 6224–6234. [CrossRef]
27. Cruz, L.; Biryukov, J.; Conway, M.J.; Meyers, C. Cleavage of the HPV16 minor capsid protein L2 during virion morphogenesis ablates the requirement for cellular furin during de novo infection. Viruses 2015, 7, 5813–5830. [CrossRef]
28. Buck, C.B.; Pastrana, D.V.; Lowy, D.R.; Schiller, J.T. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 2004, 78, 751–757. [CrossRef]
29. Buck, C.B.; Thompson, C.D.; Pang, Y.Y.; Lowy, D.R.; Schiller, J.T. Maturation of papillomavirus capsids. J. Virol. 2005, 79, 2839–2846. [CrossRef]
30. Cerqueira, C.; Samperio Ventayol, P.; Vogeley, C.; Schelhaas, M. Kallikrein-8 Proteolytically Processes Human Papillomaviruses in the Extracellular Space to Facilitate Entry into Host Cells. J. Virol. 2015, 89, 7038–7052. [CrossRef]
31. DiGiuseppe, S.; Bienkowska-Haba, M.; Hilbig, L.; Sapp, M. The nuclear retention signal of HPV16 L2 protein is essential for incoming viral genome to transverse the trans-Golgi network. Virology 2014, 458–459, 93–105. [CrossRef] [PubMed]
32. Aydin, I.; Villalonga-Planells, R.; Greune, L.; Bronnimann, M.P.; Calton, C.M.; Becker, M.; Lai, K.-Y.; Campos, S.K.; Schmidt, M.A.; Schelhaas, M. A central region in the minor capsid protein of papillomaviruses facilitates viral genome tethering and membrane penetration for mitotic nuclear entry. PLoS Pathog. 2017, 13, e1006308. [CrossRef] [PubMed]
33. Israr, M.; Rosenthal, D.; Frejo-Navarro, L.; DeVoti, J.; Meyers, C.; Bonagura, V.R. Microarray analysis of human keratinocytes from different anatomic sites reveals site-specific immune signaling and responses to human papillomavirus type 16 transfection. Mol. Med. 2018, 24, 23. [CrossRef] [PubMed]
34. Vey, M.; Schäfer, W.; Reis, B.; Ohuchi, R.; Britt, W.; Garten, W.; Klenk, H.D.; Radsak, K. Proteolytic processing of human cytomegalovirus glycoprotein B (gpUL55) is mediated by the human endoprotease furin. Virology 1995, 206, 746–749. [CrossRef]
35. Spiesschaert, B.; Stephanowitz, H.; Krause, E.; Osterrieder, N.; Azab, W. Glycoprotein B of equine herpesvirus type 1 has two recognition sites for subtilisin-like proteases that are cleaved by furin. J. Gen. Virol. 2016, 97, 1218–1228. [CrossRef] [PubMed]
36. Glauser, D.L.; Milho, R.; Frederico, B.; May, J.S.; Kratz, A.S.; Gillet, L.; Stevenson, P.G. Glycoprotein B cleavage is important for murid herpesvirus 4 to infect myeloid cells. J. Virol. 2013, 87, 10828–10842. [CrossRef] [PubMed]
37. Oliver, S.L.; Sommer, M.; Zerboni, L.; Rajamani, J.; Grose, C.; Arvin, A.M. Mutagenesis of varicella-zoster virus glycoprotein B: Putative fusion loop residues are essential for viral replication, and the furin cleavage motif contributes to pathogenesis in skin tissue in vivo. J. Virol. 2009, 83, 7495–7506. [CrossRef]
38. Sorem, J.; Longnecker, R. Cleavage of Epstein-Barr virus glycoprotein B is required for full function in cell-cell fusion with both epithelial and B cells. J. Gen. Virol. 2009, 90, 591–595. [CrossRef]
39. Stangherlin, L.M.; de Paula, F.N.; Icimoto, M.Y.; Ruiz, L.G.P.; Nogueira, M.L.; Braz, A.S.K.; Juliano, L.; da Silva, M.C.C. Positively selected sites at HCMV gB furin processing region and their effects in cleavage efficiency. Front. Microbiol. 2017, 8, 934. [CrossRef]
40. Sirohi, D.; Chen, Z.; Sun, L.; Klose, T.; Pierson, T.C.; Rossmann, M.G.; Kuhn, R.J. The 3.8 Å resolution cryo-EM structure of Zika virus. Science 2016, 352, 467–470. [CrossRef]
41. Mukhopadhyay, S.; Kuhn, R.J.; Rossmann, M.G. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 2005, 3, 13–22. [CrossRef] [PubMed]
42. Zybert, I.A.; van der Ende-Metselaar, H.; Wilschut, J.; Smit, J.M. Functional importance of dengue virus maturation: Infectious properties of immature virions. J. Gen. Virol. 2008, 89, 3047–3051. [CrossRef] [PubMed]
43. da Silva Voorham, J.M.; Rodenhuis-Zybert, I.A.; Ayala Nunez, N.V.; Colpitts, T.M.; van der Ende-Metselaar, H.; Fikrig, E.; Diamond, M.S.; Wilschut, J.; Smit, J.M. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS ONE 2012, 7, e29957. [CrossRef] [PubMed]
44. Miner, J.J.; Diamond, M.S. Zika virus pathogenesis and tissue tropism. Cell Host Microbe 2017, 21, 134–142. [CrossRef] [PubMed]
45. Paz-Bailey, G.; Rosenberg, E.S.; Doyle, K.; Munoz-Jordan, J.; Santiago, G.A.; Klein, L.; Perez-Padilla, J.; Medina, F.A.; Waterman, S.H.; Gubern, C.G.; et al. Persistence of Zika virus in body fluids-preliminary report. N. Engl. J. Med. 2017. [CrossRef]
46. Seidah, N.G.; Day, R.; Hamelin, J.; Gaspar, A.; Collard, M.W.; Chrétien, M. Testicular expression of PC4 in the rat: Molecular diversity of a novel germ cell-specific Kex2/subtilisin-like proprotein convertase. Mol. Endocrinol. 1992, 6, 1559–1570. [PubMed]
47. Fischl, W.; Elshuber, S.; Schrauf, S.; Mandl, C.W. Changing the protease specificity for activation of a flavivirus, tick-borne encephalitis virus. J. Virol. 2008, 82, 8272–8282. [CrossRef]
48. Brault, J.B.; Khou, C.; Basset, J.; Coquand, L.; Fraisier, V.; Frenkiel, M.P.; Goud, B.; Manuguerra, J.C.; Pardigon, N.; Baffet, A.D. Comparative analysis between flaviviruses reveals specific neural stem cell tropism for Zika virus in the mouse developing neocortex. EBioMedicine 2016, 10, 71–76. [CrossRef]
49. Garcez, P.P.; Loiola, E.C.; Madeiro da Costa, R.; Higa, L.M.; Trindade, P.; Delvecchio, R.; Nascimento, J.M.; Brindeiro, R.; Tanuri, A.; Rehen, S.K. Zika virus impairs growth in human neurospheres and brain organoids. Science 2016, 352, 816–818. [CrossRef]
50. Voss, J.E.; Vaney, M.C.; Duquerroy, S.; Vonrhein, C.; Girard-Blanc, C.; Crublet, E.; Thompson, A.; Bricogne, G.; Rey, F.A. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 2010, 468, 709–712. [CrossRef]
51. Zhang, X.; Fugère, M.; Day, R.; Kielian, M. Furin processing and proteolytic activation of Semliki Forest virus. J. Virol. 2003, 77, 2981–2989. [CrossRef] [PubMed]
52. Ozden, S.; Lucas-Hourani, M.; Ceccaldi, P.-E.; Basak, A.; Valentine, M.; Benjannet, S.; Hamelin, J.; Jacob, Y.; Mamchaoui, K.; Mouly, V.; et al. Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: Impairment of the maturation of the E2 surface glycoprotein. J. Biol. Chem. 2008, 283, 21899–21908. [CrossRef] [PubMed]
53. Millet, J.K.; Whittaker, G.R. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015, 202, 120–134. [CrossRef] [PubMed]
54. Bosch, B.J.; Bartelink, W.; Rottier, P.J. Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J. Virol. 2008, 82, 8887–8890. [CrossRef] [PubMed]
55. Simmons, G.; Bertram, S.; Glowacka, I.; Steffen, I.; Chaipan, C.; Agudelo, J.; Lu, K.; Rennekamp, A.J.; Hofmann, H.; Bates, P.; et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. Virology 2011, 413, 265–274. [CrossRef]
56. Yamada, Y.; Liu, D.X. Proteolytic activation of the spike protein at a novel RRRR/S motif is implicated in furin-dependent entry, syncytium formation, and infectivity of coronavirus infectious bronchitis virus in cultured cells. J. Virol. 2009, 83, 8744–8758. [CrossRef]
57. Belouzard, S.; Chu, V.C.; Whittaker, G.R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. USA 2009, 106, 5871–5876. [CrossRef]
58. Millet, J.K.; Whittaker, G.R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. USA 2014, 111, 15214–15219. [CrossRef]
59. Park, J.E.; Li, K.; Barlan, A.; Fehr, A.R.; Perlman, S.; McCray, P.B., Jr.; Gallagher, T. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc. Natl. Acad. Sci. USA 2016, 113, 12262–12267. [CrossRef]
60. Tay, F.P.; Huang, M.; Wang, L.; Yamada, Y.; Liu, D.X. Characterization of cellular furin content as a potential factor determining the susceptibility of cultured human and animal cells to coronavirus infectious bronchitis virus infection. Virology 2012, 433, 421–430. [CrossRef]
61. Gu, J.; Gong, E.; Zhang, B.; Zheng, J.; Gao, Z.; Zhong, Y.; Zou, W.; Zhan, J.; Wang, S.; Xie, Z.; et al. Multiple organ infection and the pathogenesis of SARS. J. Exp. Med. 2005, 202, 415–424. [CrossRef] [PubMed]
62. Matsuyama, S.; Shirato, K.; Kawase, M.; Terada, Y.; Kawachi, K.; Fukushi, S.; Kamitani, W. Middle East respiratory syndrome coronavirus spike protein is not activated directly by cellular furin during viral entry into target cells. J. Virol. 2018, 92, e00683-18. [CrossRef] [PubMed]
63. Iwata-Yoshikawa, N.; Okamura, T.; Shimizu, Y.; Hasegawa, H.; Takeda, M.; Nagata, N. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J. Virol. 2019, 93, e01815-18. [CrossRef] [PubMed]
64. Le Coupanec, A.; Desforges, M.; Meessen-Pinard, M.; Dubé, M.; Day, R.; Seidah, N.G.; Talbot, P.J. Cleavage of a neuroinvasive human respiratory virus spike glycoprotein by proprotein convertases modulates neurovirulence and virus spread within the central nervous system. PLoS Pathog. 2015, 11, e1005261. [CrossRef] [PubMed]
65. Li, W.; Wicht, O.; van Kuppeveld, F.J.; He, Q.; Rottier, P.J.; Bosch, B.J. A single point mutation creating a furin cleavage site in the spike protein renders porcine epidemic diarrhea coronavirus trypsin independent for cell entry and fusion. J. Virol. 2015, 89, 8077–8081. [CrossRef] [PubMed]
66. Zarkik, S.; Decroly, E.; Wattiez, R.; Seidah, N.G.; Burny, A.; Ruysschaert, J.M. Comparative processing of bovine leukemia virus envelope glycoprotein gp72 by subtilisin/kexin-like mammalian convertases. FEBS Lett. 1997, 406, 205–210. [CrossRef]
67. Sjöberg, M.; Wallin, M.; Lindqvist, B.; Garoff, H. Furin cleavage potentiates the membrane fusion-controlling intersubunit disulfide bond isomerization activity of leukemia virus Env. J. Virol. 2006, 80, 5540–5551. [CrossRef] [PubMed]
68. Sjöberg, M.; Wu, S.R.; Löving, R.; Rantalainen, K.; Lindqvist, B.; Garoff, H. Furin cleavage of the Moloney murine leukemia virus Env precursor reorganizes the spike structure. Proc. Natl. Acad. Sci. USA 2014, 111, 6034–6039. [CrossRef]
69. Löving, R.; Kronqvist, M.; Sjöberg, M.; Garoff, H. Cooperative cleavage of the R peptide in the Env trimer of Moloney murine leukemia virus facilitates its maturation for fusion competence. J. Virol. 2011, 85, 3262–3269. [CrossRef]
70. Löving, R.; Wu, S.R.; Sjöberg, M.; Lindqvist, B.; Garoff, H. Maturation cleavage of the murine leukemia virus Env precursor separates the transmembrane subunits to prime it for receptor triggering. Proc. Natl. Acad. Sci. USA 2012, 109, 7735–7740. [CrossRef]
71. Vollenweider, F.; Benjannet, S.; Decroly, E.; Savaria, D.; Lazure, C.; Thomas, G.; Chrétien, M.; Seidah, N.G. Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. Biochem. J. 1996, 314, 521–532. [CrossRef] [PubMed]
72. Hallenberger, S.; Moulard, M.; Sordel, M.; Klenk, H.D.; Garten, W. The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells. J. Virol. 1997, 71, 1036–1045. [PubMed]
73. Sarkar, A.; Bale, S.; Behrens, A.J.; Kumar, S.; Sharma, S.K.; de Val, N.; Pallesen, J.; Irimia, A.; Diwanji, D.C.; Stanfield, R.L.; et al. Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. Nat. Commun. 2018, 9, 1956. [CrossRef] [PubMed]
74. Pasquato, A.; Dettin, M.; Basak, A.; Gambaretto, R.; Tonin, L.; Seidah, N.G.; Di Bello, C. Heparin enhances the furin cleavage of HIV-1 gp160 peptides. FEBS Lett. 2007, 581, 5807–5813. [CrossRef] [PubMed]
75. Tong, Y.; Tong, S.; Zhao, X.; Wang, J.; Jun, J.; Park, J.; Wands, J.; Li, J. Initiation of duck hepatitis B virus infection requires cleavage by a furin-like protease. J. Virol. 2010, 84, 4569–4578. [CrossRef]
76. Volchkov, V.E.; Feldmann, H.; Volchkova, V.A.; Klenk, H.D. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. USA 1998, 95, 5762–5767. [CrossRef]
77. Sanchez, A.; Yang, Z.Y.; Xu, L.; Nabel, G.J.; Crews, T.; Peters, C.J. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 1998, 72, 6442–6447.
78. Volchkov, V.E.; Volchkova, V.A.; Ströher, U.; Becker, S.; Dolnik, O.; Cieplik, M.; Garten, W.; Klenk, H.D.; Feldmann, H. Proteolytic processing of Marburg virus glycoprotein. Virology 2000, 268, 1–6. [CrossRef]
79. Wool-Lewis, R.J.; Bates, P. Endoproteolytic processing of the ebola virus envelope glycoprotein: Cleavage is not required for function. J. Virol. 1999, 73, 1419–1426.
80. Neumann, G.; Feldmann, H.; Watanabe, S.; Lukashevich, I.; Kawaoka, Y. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J. Virol. 2002, 76, 406–410. [CrossRef]
81. Neumann, G.; Geisbert, T.W.; Ebihara, H.; Geisbert, J.B.; Daddario-DiCaprio, K.M.; Feldmann, H.; Kawaoka, Y. Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J. Virol. 2007, 81, 2995–2998. [CrossRef] [PubMed]
82. Chandran, K.; Sullivan, N.J.; Felbor, U.; Whelan, S.P.; Cunningham, J.M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005, 308, 1643–1645. [CrossRef] [PubMed]
83. Schornberg, K.; Matsuyama, S.; Kabsch, K.; Delos, S.; Bouton, A.; White, J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 2006, 80, 4174–4178. [CrossRef] [PubMed]
84. Misasi, J.; Chandran, K.; Yang, J.Y.; Considine, B.; Filone, C.M.; Côté, M.; Sullivan, N.; Fabozzi, G.; Hensley, L.; Cunningham, J. Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J. Virol. 2012, 86, 3284–3292. [CrossRef] [PubMed]
85. Kaletsky, R.L.; Simmons, G.; Bates, P. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J. Virol. 2007, 81, 13378–13384. [CrossRef] [PubMed]
86. Bale, S.; Liu, T.; Li, S.; Wang, Y.; Abelson, D.; Fusco, M.; Woods, V.L., Jr.; Saphire, E.O. Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. PLoS Negl. Trop. Dis. 2011, 5, e1395. [CrossRef] [PubMed]
87. Sanchez, A.J.; Vincent, M.J.; Erickson, B.R.; Nichol, S.T. Crimean-Congo hemorrhagic fever virus glycoprotein precursor is cleaved by furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J. Virol. 2006, 80, 514–525. [CrossRef]
88. Bergeron, É.; Zivcec, M.; Chakrabarti, A.K.; Nichol, S.T.; Albariño, C.G.; Spiropoulou, C.F. Recovery of recombinant Crimean-Congo hemorrhagic fever virus reveals a function for non-structural glycoproteins cleavage by furin. PLoS Pathog. 2015, 11, e1004879. [CrossRef]
89. Urata, S.; Yun, N.; Pasquato, A.; Paessler, S.; Kunz, S.; de la Torre, J.C. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J. Virol. 2011, 85, 795–803. [CrossRef]
90. Rojek, J.M.; Pasqual, G.; Sanchez, A.B.; Nguyen, N.-T.; de la Torre, J.C.; Kunz, S. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J. Virol. 2010, 84, 573–584. [CrossRef]
91. Ortmann, D.; Ohuchi, M.; Angliker, H.; Shaw, E.; Garten, W.; Klenk, H.D. Proteolytic cleavage of wild type and mutants of the F protein of human parainfluenza virus type 3 by two subtilisin-like endoproteases, furin and Kex2. J. Virol. 1994, 68, 2772–2776. [PubMed]
92. Watanabe, M.; Hirano, A.; Stenglein, S.; Nelson, J.; Thomas, G.; Wong, T.C. Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus. J. Virol. 1995, 69, 3206–3210. [PubMed]
93. Bolt, G.; Pedersen, I.R. The role of subtilisin-like proprotein convertases for cleavage of the measles virus fusion glycoprotein in different cell types. Virology 1998, 252, 387–398. [CrossRef] [PubMed]
94. Nayak, B.; Kumar, S.; Collins, P.L.; Samal, S.K. Molecular characterization and complete genome sequence of avian paramyxovirus type 4 prototype strain duck/Hong Kong/D3/75. Virol. J. 2008, 5, 124. [CrossRef] [PubMed]
95. Samuel, A.S.; Kumar, S.; Madhuri, S.; Collins, P.L.; Samal, S.K. Complete sequence of the genome of avian paramyxovirus type 9 and comparison with other paramyxoviruses. Virus Res. 2009, 142, 10–18. [CrossRef] [PubMed]
96. Subbiah, M.; Khattar, S.K.; Collins, P.L.; Samal, S.K. Mutations in the fusion protein cleavage site of avian paramyxovirus serotype 2 increase cleavability and syncytium formation but do not increase viral virulence in chickens. J. Virol. 2011, 85, 5394–5405. [CrossRef] [PubMed]
97. Xiao, S.; Khattar, S.K.; Subbiah, M.; Collins, P.L.; Samal, S.K. Mutation of the f-protein cleavage site of avian paramyxovirus type 7 results in furin cleavage, fusion promotion, and increased replication in vitro but not increased replication, tissue tropism, or virulence in chickens. J. Virol. 2012, 86, 3828–3838. [CrossRef] [PubMed]
98. Kim, S.H.; Xiao, S.; Shive, H.; Collins, P.L.; Samal, S.K. Mutations in the fusion protein cleavage site of avian paramyxovirus serotype 4 confer increased replication and syncytium formation in vitro but not increased replication and pathogenicity in chickens and ducks. PLoS ONE 2013, 8, e50598. [CrossRef]
99. Manoharan, V.K.; Varghese, B.P.; Paldurai, A.; Samal, S.K. Effect of fusion protein cleavage site sequence on generation of a genotype VII Newcastle disease virus vaccine. PLoS ONE 2018, 13, e0197253. [CrossRef]
100. González-Reyes, L.; Ruiz-Argüello, M.B.; García-Barreno, B.; Calder, L.; López, J.A.; Albar, J.P.; Skehel, J.J.; Wiley, D.C.; Melero, J.A. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc. Natl. Acad. Sci. USA 2001, 98, 9859–9864. [CrossRef]
101. Krzyzaniak, M.A.; Zumstein, M.T.; Gerez, J.A.; Picotti, P.; Helenius, A. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013, 9, e1003309. [CrossRef] [PubMed]
102. Moll, M.; Diederich, S.; Klenk, H.D.; Czub, M.; Maisner, A. Ubiquitous activation of the Nipah virus fusion protein does not require a basic amino acid at the cleavage site. J. Virol. 2004, 78, 9705–9712. [CrossRef]
103. Pager, C.T.; Dutch, R.E. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. J. Virol. 2005, 79, 12714–12720. [CrossRef] [PubMed]
104. Rawling, J.; Cano, O.; Garcin, D.; Kolakofsky, D.; Melero, J.A. Recombinant Sendai viruses expressing fusion proteins with two furin cleavage sites mimic the syncytial and receptor-independent infection properties of respiratory syncytial virus. J. Virol. 2011, 85, 2771–2780. [CrossRef] [PubMed]
105. Garten, W.; Braden, C.; Arendt, A.; Peitsch, C.; Baron, J.; Lu, Y.; Pawletko, K.; Hardes, K.; Steinmetzer, T.; Böttcher-Friebertshäuser, E. Influenza virus activating host proteases: Identification, localization and inhibitors as potential therapeutics. Eur. J. Cell Biol. 2015, 94, 375–383. [CrossRef] [PubMed]
106. Kido, H.; Okumura, Y.; Takahashi, E.; Pan, H.Y.; Wang, S.; Yao, D.; Yao, M.; Chida, J.; Yano, M. Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure. Biochim. Biophys. Acta 2012, 1824, 186–194. [CrossRef] [PubMed]
107. Chaipan, C.; Kobasa, D.; Bertram, S.; Glowacka, I.; Steffen, I.; Tsegaye, T.S.; Takeda, M.; Bugge, T.H.; Kim, S.; Park, Y.; et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 2009, 83, 3200–3211. [CrossRef]
108. Böttcher, E.; Matrosovich, T.; Beyerle, M.; Klenk, H.D.; Garten, W.; Matrosovich, M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 2006, 80, 9896–9898. [CrossRef]
109. Baron, J.; Tarnow, C.; Mayoli-Nüssle, D.; Schilling, E.; Meyer, D.; Hammami, M.; Schwalm, F.; Steinmetzer, T.; Guan, Y.; Garten, W.; et al. Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses. J. Virol. 2013, 87, 1811–1820. [CrossRef]
110. Tse, L.V.; Hamilton, A.M.; Friling, T.; Whittaker, G.R. A novel activation mechanism of avian influenza virus H9N2 by furin. J. Virol. 2014, 88, 1673–1683. [CrossRef]
111. Stieneke-Gröber, A.; Vey, M.; Angliker, H.; Shaw, E.; Thomas, G.; Roberts, C.; Klenk, H.D.; Garten, W. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J. 1992, 11, 2407–2414. [CrossRef] [PubMed]
112. Horimoto, T.; Nakayama, K.; Smeekens, S.P.; Kawaoka, Y. Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses. J. Virol. 1994, 68, 6074–6078. [PubMed]
113. Walker, J.A.; Molloy, S.S.; Thomas, G.; Sakaguchi, T.; Yoshida, T.; Chambers, T.M.; Kawaoka, Y. Sequence specificity of furin, a proprotein-processing endoprotease, for the hemagglutinin of a virulent avian influenza virus. J. Virol. 1994, 68, 1213–1218. [PubMed]
114. Morsy, J.; Garten, W.; Rott, R. Activation of an influenza virus A/turkey/Oregon/71 HA insertion variant by the subtilisin-like endoprotease furin. Virology 1994, 202, 988–991. [CrossRef] [PubMed]
115. Feldmann, A.; Schäfer, M.K.; Garten, W.; Klenk, H.D. Targeted infection of endothelial cells by avian influenza virus A/FPV/Rostock/34 (H7N1) in chicken embryos. J. Virol. 2000, 74, 8018–8027. [CrossRef] [PubMed]
116. Hatta, M.; Gao, P.; Halfmann, P.; Kawaoka, Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001, 293, 1840–1842. [CrossRef] [PubMed]
117. Okumura, Y.; Takahashi, E.; Yano, M.; Ohuchi, M.; Daidoji, T.; Nakaya, T.; Böttcher, E.; Garten, W.; Klenk, H.D.; Kido, H. Novel type II transmembrane serine proteases, MSPL and TMPRSS13, Proteolytically activate membrane fusion activity of the hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication. J. Virol. 2010, 84, 5089–5096. [CrossRef] [PubMed]
118. López-Vallejo, F.; Martínez-Mayorga, K. Furin inhibitors: Importance of the positive formal charge and beyond. Bioorg. Med. Chem. 2012, 20, 4462–4471. [CrossRef] [PubMed]
119. Coppola, J.M.; Bhojani, M.S.; Ross, B.D.; Rehemtulla, A. A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 2008, 10, 363–370. [CrossRef]
120. Komiyama, T.; Coppola, J.M.; Larsen, M.J.; van Dort, M.E.; Ross, B.D.; Day, R.; Rehemtulla, A.; Fuller, R.S. Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J. Biol. Chem. 2009, 284, 15729–15738. [CrossRef]
121. Jiao, G.-S.; Cregar, L.; Wang, J.; Millis, S.Z.; Tang, C.; O’Malley, S.; Johnson, A.T.; Sareth, S.; Larson, J.; Thomas, G. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc. Natl. Acad. Sci. USA 2006, 103, 19707–19712. [CrossRef] [PubMed]
122. Ramos-Molina, B.; Lick, A.N.; Blanco, E.H.; Posada-Salgado, J.A.; Martinez-Mayorga, K.; Johnson, A.T.; Jiao, G.-S.; Lindberg, I. Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays. Biochem. Pharmacol. 2015, 96, 107–118. [CrossRef] [PubMed]
123. Becker, G.L.; Sielaff, F.; Than, M.E.; Lindberg, I.; Routhier, S.; Day, R.; Lu, Y.; Garten, W.; Steinmetzer, T. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J. Med. Chem. 2010, 53, 1067–1075. [CrossRef] [PubMed]
124. Levesque, C.; Fugere, M.; Kwiatkowska, A.; Couture, F.; Desjardins, R.; Routhier, S.; Moussette, P.; Prahl, A.; Lammek, B.; Appel, J.R.; et al. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J. Med. Chem. 2012, 55, 10501–10511. [CrossRef] [PubMed]
125. Shiryaev, S.A.; Remacle, A.G.; Ratnikov, B.I.; Nelson, N.A.; Savinov, A.Y.; Wei, G.; Bottini, M.; Rega, M.F.; Parent, A.; Desjardins, R.; et al. Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J. Biol. Chem. 2007, 282, 20847–20853. [CrossRef] [PubMed]
126. Basak, A.; Khatib, A.-M.; Mohottalage, D.; Basak, S.; Kolajova, M.; Bag, S.S.; Basak, A. A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A., B and proVEGF-C. PLoS ONE 2009, 4, e7700. [CrossRef]
127. Remacle, A.G.; Gawlik, K.; Golubkov, V.S.; Cadwell, G.W.; Liddington, R.C.; Cieplak, P.; Millis, S.Z.; Desjardins, R.; Routhier, S.; Yuan, X.W.; et al. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int. J. Biochem. Cell Biol. 2010, 42, 987–995. [CrossRef]
128. Becker, G.L.; Lu, Y.; Hardes, K.; Strehlow, B.; Levesque, C.; Lindberg, I.; Sandvig, K.; Bakowsky, U.; Day, R.; Garten, W.; et al. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J. Biol. Chem. 2012, 287, 21992–22003. [CrossRef]
129. Gagnon, H.; Beauchemin, S.; Kwiatkowska, A.; Frédéric Couture, F.; D’Anjou, F.; Levesque, C.; Dufour, F.; Desbiens, A.R.; Vaillancourt, R.; Bernard, S.; et al. Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin. J. Med. Chem. 2014, 57, 29–41. [CrossRef]
130. Kwiatkowska, A.; Couture, F.; Levesque, C.; Ly, K.; Desjardins, R.; Beauchemin, S.; Prahl, A.; Lammek, B.; Neugebauer, W.; Dory, Y.L.; et al. Design, synthesis, and structure−activity relationship studies of a potent PACE4 inhibitor. J. Med. Chem. 2014, 57, 98–109. [CrossRef]
131. Lu, Y.; Hardes, K.; Dahms, S.O.; Böttcher-Friebertshäuser, E.; Steinmetzer, T.; Than, M.E.; Klenk, H.-D.; Garten, W. Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells. Antivir. Res. 2015, 120, 89–100. [CrossRef] [PubMed]
132. Hardes, K.; Becker, G.L.; Lu, Y.; Dahms, S.O.; Kçhler, S.; Beyer, W.; Sandvig, K.; Yamamoto, H.; Lindberg, I.; Lisa Walz, L.; et al. Novel furin inhibitors with potent anti-infectious activity. Chem. Med. Chem. 2015, 10, 1218–1231. [CrossRef] [PubMed]
133. Ivanova, T.; Hardes, K.; Kallis, S.; Dahms, S.O.; Than, M.E.; Kenzel, S.; Eva Bçttcher-Friebertshäuser, E.; Lindberg, I.; Jiao, G.-S.; Bartenschlager, R.; et al. Optimization of substrate-analogue furin inhibitors. Chem. Med. Chem. 2017, 12, 1953–1968. [CrossRef] [PubMed]
134. Hardes, K.; Ivanova, T.; Thaa, B.; McInerney, G.M.; Klokk, T.I.; Sandvig, K.; Künzel, S.; Lindberg, I.; Steinmetzer, T. Elongated and shortened peptidomimetic inhibitors of the proprotein convertase furin. Chem. Med. Chem. 2017, 12, 613–620. [CrossRef] [PubMed]
135. Kouretova, J.; Hammamy, M.Z.; Epp, A.; Hardes, K.; Kallis, S.; Zhang, L.; Hilgenfeld, R.; Bartenschlager, R.; Steinmetzer, T. Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication. J. Enzyme Inhib. Med. Chem. 2017, 32, 712–721. [CrossRef] [PubMed]
136. Van Lam van, T.; Ivanova, T.; Hardes, K.; Heindl, M.R.; Morty, R.E.; Bçttcher-Friebertshäuser, E.; Lindberg, I.; Than, M.E.; Dahms, S.O.; Steinmetzer, T. Design, synthesis, and characterization of macrocyclic inhibitors of the proprotein convertase furin. Chem. Med. Chem. 2019, 14, 673–685. [CrossRef]
137. Cameron, A.; Appel, J.; Houghten, R.A.; Lindberg, I. Polyarginines are potent furin inhibitors. J. Biol. Chem. 2000, 275, 36741–36749. [CrossRef]
138. Fugère, M.; Appel, J.; Houghten, R.A.; Lindberg, I.; Day, R. Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol. Pharmacol. 2007, 71, 323–332. [CrossRef]
139. Ramos-Molina, B.; Lick, A.N.; Nasrolahi Shirazi, A.; Oh, D.; Tiwari, R.; El-Sayed, N.S.; Parang, K.; Lindberg, I. Cationic cell-penetrating peptides are potent furin inhibitors. PLoS ONE 2015, 10, e0130417. [CrossRef]
140. Komiyama, T.; Fuller, R.S. Engineered eglin c variants inhibit yeast and human proprotein processing proteases, Kex2 and furin. Biochemistry 2000, 39, 15156–15165. [CrossRef]
141. Lu, W.; Zhang, W.; Molloy, S.S.; Thomas, G.; Ryan, K.; Chiang, Y.; Anderson, S.; Laskowski, M., Jr. Arg15-Lys17-Arg18 turkey ovomucoid third domain inhibits human furin. J. Biol. Chem. 1993, 268, 14583–14585. [PubMed]
142. Van Rompaey, L.; Ayoubi, T.; Van De Ven, W.; Marynen, P. Inhibition of intracellular proteolytic processing of soluble proproteins by an engineered α2-macroglobulin containing a furin recognition sequence in the bait region. Biochem. J. 1997, 326, 507–514. [CrossRef] [PubMed]
143. Kibler, K.V.; Miyazato, A.; Yedavalli, V.S.R.K.; Dayton, A.I.; Jacobs, B.L.; Dapolito, G.; Kim, S.-J.; Jeang, K.-T. Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. J. Biol. Chem. 2004, 279, 49055–49063. [CrossRef] [PubMed]
144. Stroher, U.; Willihnganz, L.; Jean, F.; Feldmann, H. Blockage of filoviral glycoprotein processing by use of a protein-based inhibitor. J. Infect. Dis. 2007, 196 (Suppl. 2), S271. [CrossRef] [PubMed]
145. Jean, F.; Thomas, L.; Molloy, S.S.; Liu, G.; Jarvis, M.A.; Nelson, J.A.; Thomas, G. A protein-based therapeutic for human cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 2000, 97, 2864–2869. [CrossRef] [PubMed]